Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda.

Sacktor N, Nakasujja N, Skolasky RL, Robertson K, Musisi S, Ronald A, Katabira E, Clifford DB.

Neurology. 2009 Jan 13;72(2):165-70. doi: 10.1212/01.wnl.0000339042.96109.86.

2.

NMDA receptor activation by HIV-Tat protein is clade dependent.

Li W, Huang Y, Reid R, Steiner J, Malpica-Llanos T, Darden TA, Shankar SK, Mahadevan A, Satishchandra P, Nath A.

J Neurosci. 2008 Nov 19;28(47):12190-8. doi: 10.1523/JNEUROSCI.3019-08.2008.

3.

Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection.

Kiwanuka N, Laeyendecker O, Robb M, Kigozi G, Arroyo M, McCutchan F, Eller LA, Eller M, Makumbi F, Birx D, Wabwire-Mangen F, Serwadda D, Sewankambo NK, Quinn TC, Wawer M, Gray R.

J Infect Dis. 2008 Mar 1;197(5):707-13. doi: 10.1086/527416.

PMID:
18266607
4.

Updated research nosology for HIV-associated neurocognitive disorders.

Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE.

Neurology. 2007 Oct 30;69(18):1789-99. Epub 2007 Oct 3.

5.

Impact of human immunodeficiency virus (HIV) subtypes on HIV-associated neurological disease.

Liner KJ 2nd, Hall CD, Robertson KR.

J Neurovirol. 2007 Aug;13(4):291-304. Review.

PMID:
17849313
6.

HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads.

Baeten JM, Chohan B, Lavreys L, Chohan V, McClelland RS, Certain L, Mandaliya K, Jaoko W, Overbaugh J.

J Infect Dis. 2007 Apr 15;195(8):1177-80. Epub 2007 Mar 2.

PMID:
17357054
7.

Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort.

Kaleebu P, Nankya IL, Yirrell DL, Shafer LA, Kyosiimire-Lugemwa J, Lule DB, Morgan D, Beddows S, Weber J, Whitworth JA.

J Acquir Immune Defic Syndr. 2007 May 1;45(1):28-33.

PMID:
17310935
8.

Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa.

Wong MH, Robertson K, Nakasujja N, Skolasky R, Musisi S, Katabira E, McArthur JC, Ronald A, Sacktor N.

Neurology. 2007 Jan 30;68(5):350-5.

PMID:
17261681
9.

Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004.

Hemelaar J, Gouws E, Ghys PD, Osmanov S.

AIDS. 2006 Oct 24;20(16):W13-23.

PMID:
17053344
10.

The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia.

Dunfee RL, Thomas ER, Gorry PR, Wang J, Taylor J, Kunstman K, Wolinsky SM, Gabuzda D.

Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15160-5. Epub 2006 Oct 2.

11.

Genetic attributes of cerebrospinal fluid-derived HIV-1 env.

Pillai SK, Pond SL, Liu Y, Good BM, Strain MC, Ellis RJ, Letendre S, Smith DM, G√ľnthard HF, Grant I, Marcotte TD, McCutchan JA, Richman DD, Wong JK.

Brain. 2006 Jul;129(Pt 7):1872-83. Epub 2006 May 30.

PMID:
16735456
12.

Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype.

Vasan A, Renjifo B, Hertzmark E, Chaplin B, Msamanga G, Essex M, Fawzi W, Hunter D.

Clin Infect Dis. 2006 Mar 15;42(6):843-52. Epub 2006 Feb 9. Erratum in: Clin Infect Dis. 2006 Sep 1;43(5):671.

PMID:
16477563
13.

The International HIV Dementia Scale: a new rapid screening test for HIV dementia.

Sacktor NC, Wong M, Nakasujja N, Skolasky RL, Selnes OA, Musisi S, Robertson K, McArthur JC, Ronald A, Katabira E.

AIDS. 2005 Sep 2;19(13):1367-74.

PMID:
16103767
14.
15.

Comparison of mother-to-child transmission rates in Ugandan women with subtype A versus D HIV-1 who received single-dose nevirapine prophylaxis: HIV Network For Prevention Trials 012.

Eshleman SH, Guay LA, Mwatha A, Brown E, Musoke P, Mmiro F, Jackson JB.

J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):593-7.

PMID:
16044013
16.

HIV-1 dynamics in vivo: implications for therapy.

Simon V, Ho DD.

Nat Rev Microbiol. 2003 Dec;1(3):181-90. Review.

PMID:
15035022
17.
18.

Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda.

Kaleebu P, French N, Mahe C, Yirrell D, Watera C, Lyagoba F, Nakiyingi J, Rutebemberwa A, Morgan D, Weber J, Gilks C, Whitworth J.

J Infect Dis. 2002 May 1;185(9):1244-50. Epub 2002 Apr 16.

PMID:
12001041
19.

Predominance of HIV type 1 subtype G among commercial sex workers from Kinshasa, Democratic Republic of Congo.

Yang C, Dash B, Hanna SL, Frances HS, Nzilambi N, Colebunders RC, St Louis M, Quinn TC, Folks TM, Lal RB.

AIDS Res Hum Retroviruses. 2001 Mar 1;17(4):361-5.

PMID:
11242522
20.

Lentivirus infection in the brain induces matrix metalloproteinase expression: role of envelope diversity.

Johnston JB, Jiang Y, van Marle G, Mayne MB, Ni W, Holden J, McArthur JC, Power C.

J Virol. 2000 Aug;74(16):7211-20.

Supplemental Content

Support Center